Neuromodulation — the use of electrical or chemical stimulation to modulate neural activity — is the most commercially established segment of the neurotechnology market. From deep brain stimulation (DBS) for Parkinson's disease to spinal cord stimulation for chronic pain and vagus nerve stimulation for epilepsy, neuromodulation devices are improving outcomes for millions of patients.
Neuromodulation devices deliver targeted stimulation to specific neural circuits, modulating abnormal activity. According to neurotechnology market research, neuromodulation accounts for a significant share of the market, driven by rising prevalence of neurological disorders and expanding clinical applications. Growth is supported by advances in device design, closed-loop stimulation, and minimally invasive techniques.
Innovation includes adaptive stimulation that responds to neural signals, smaller and longer-lasting devices, and new targets for treatment-resistant conditions.
Challenges include cost, surgical risk, and long-term efficacy.
Yet the trend is clear: neuromodulation will continue to grow, and the neurotechnology market is expected to benefit as technology improves.
People Also Ask
Q: What is neuromodulation?
A: It is the use of electrical or chemical stimulation to modulate neural activity, used to treat conditions like Parkinson's disease and chronic pain.
Q: What is deep brain stimulation?
A: DBS is a neuromodulation technique that delivers electrical stimulation to specific brain regions, used for Parkinson's disease and other conditions.
Tags: #Neuromodulation #DeepBrainStimulation #DBS #Neurostimulation #ChronicPain #MarketTrends
